|
Oct 7
|
BioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD.
|
|
Jun 21
|
BioSenic signs a new subscription agreement for a maximum of EUR 2.1M in convertible bonds
|
|
Feb 2
|
BioSenic raises €500,000 in private placement of new shares with established new investors
|
|
Jan 31
|
BioSenic provides support to forthcoming European conference on graft-versus-host disease
|
|
Jan 15
|
BioSenic reaches agreement on a binding term sheet with Phebra PTY Ltd. with respect to the development of the first oral formulation of arsenic troxide for cGvHD treatment
|
|
Jan 15
|
BioSenic S.A. : Transparency notifications received from François Rieger
|
|
Jan 10
|
BioSenic appoints Dr Carole Nicco as Chief Operating Officer in addition to Chief Scientific Officer
|
|
Dec 8
|
ERRATUM: BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease
|
|
Dec 6
|
BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease
|
|
Oct 5
|
BioSenic S.A. : Information on the total number of voting rights and shares
|